<DOC>
	<DOCNO>NCT00314288</DOCNO>
	<brief_summary>The primary purpose study investigate anti-dyskinetic effect several dos sarizotan Parkinson patient order generate information dose-response relationship ( dose-finding ) .</brief_summary>
	<brief_title>Sarizotan Parkinson Patients With L-dopa-induced Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Male Female The subject outpatient Age 30 year Dyskinesias present 25 % wake day Dyskinesias least moderately disable Written informed consent Pregnancy and/or lactation Participation another study within last 30 day Dementia psychiatric illness prevents provision inform consent History allergic disorder asthma Known hypersensitivity study treatment ( ) Known hypersensitivity ACTH</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>L-dopa-induced dyskinesia</keyword>
</DOC>